Citations

Showing 10 of 108104 citations.

Outcomes of Cardiac Resynchronization Therapy with Image-Guided Left Ventricular Lead Placement at the Site of Latest Mechanical Activation: A Systematic Review and Meta-Analysis
LaPointe, Nancy M. Allen, Ali‐Ahmed, Fatima , Dalgaard, Frederik , Kosinski, Andrzej S. , Schmidler, Gillian Sanders , Al‐Khatib, Sana M. , Allen LaPointe, Nancy M , Al-Khatib, Sana M.

Mayo Clinic

Journal of Interventional Cardiology | May 21, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-10

10.1155/2022/6285894 | PMID 35655661 Get It

Aim. To assess evidence for an image-guided approach for cardiac resynchronization therapy (CRT) that targets left ventricular (LV) lead placement at the segment of latest mechanical activation. Methods. A systematic review of EMBASE and PubMed was performed for randomized controlled trials (RCTs) and prospective observational studies from October 2008 through October 2020 that compared an image-guided CRT approach with a non-image-guided approach for LV lead placement. Meta-analyses were performed to assess the association between the image-guided approach and NYHA class improvement or changes in end-systolic volume (LVESV), end-diastolic volume (LVEDV), and ejection fraction (LVEF). Results. From 5897 citations, 5 RCTs including 818 patients (426 image-guided and 392 non-image-guided) were identified. The mean age ranged from 66 to 71 years, 76% were male, and 53% had ischemic cardiomyopathy. Speckle tracking echocardiography was the primary image-guided method in all studies. LV lead placement within the segment of the latest mechanical activation (concordant) was achieved in the image-guided arm in 45% of the evaluable patients. There was a statistically significant improvement in the NYHA class at 6 months (odds ratio 1.66; 95% confidence interval (CI) [1.02, 2.69]) with the image-guided approach, but no statistically significant change in LVESV (MD −7.1%; 95% CI [−16.0, 1.8]), LVEDV (MD −5.2%; 95% CI [−15.8, 5.4]), or LVEF (MD 0.68; 95% CI [−4.36, 5.73]) versus the non-image-guided approach. Conclusion. The image-guided CRT approach was associated with improvement in the NYHA class but not echocardiographic measures, possibly due to the small sample size and a low rate of concordant LV lead placement despite using the image-guided approach. Therefore, our meta-analysis was not able to identify consistent improvement in CRT outcomes with an image-guided approach.
Shoulder Injuries in Professional Baseball Batters: Analysis of 3,414 Injuries Over an 8‐Year Period
Marigi, Erick M. , Conte, Stan, Reinholz, Anna K., Steubs, John A. , Krych, Aaron J. , Camp, Christopher L. , Camp, Christopher L. , Krych, Aaron J , Marigi, Erick , Knudsen, Michael L.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | May 21, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1016/j.asmr.2022.03.012 | PMID 35747625 Get It

Purpose To characterize the shoulder injuries experienced by baseball batters and position players (nonpitchers); to quantify the outcomes of these injuries with respect to time out of play, recurrence, and surgery rates; and to identify any injury patterns that are associated with worse outcomes. Methods Between 2011 and 2017, all Major League Baseball (MLB) and Minor League Baseball (MiLB) players who sustained shoulder injuries were identified using the MLB Health and Injury Tracking System (HITS). Injuries were included if they were sustained during baseball activity, resulted in at least 1 day missed (DM), and occurred in position players (nonpitchers). Results Over the study period, a total of 3,414 shoulder injuries occurred in batters, resulting in a sum of 68,808 DM and a mean of 22 DM per injury. Most injuries were a result of acute trauma (n = 2125; 62.2%) with throwing as the predominant activity (n = 1292; 38%). Rotator cuff strain/tears was the most common diagnosis (n = 790; 23.1%), and SLAP tears had the highest season‐ending rate (35.3%) and need for surgery (45.1%). There was a lower frequency of surgery (6.2% vs 9.2%; P = .002) and reinjury (2.03% vs 3.62%; P = .007) in the throwing shoulder vs the nonthrowing shoulder. There was an increased frequency of surgery for the front versus the back batting shoulder (8.2% vs 6.2%; P = .031) with similar DM (20.7 vs 22.2; P = .333) and return to play rates (94.0% vs 92.2%; P = .135). Conclusions During the 7‐season study period, there were a total of 3,414 shoulder injuries that resulted in nearly 70,000 days of out of play in professional baseball position players/batters (nonpitchers). Although pitchers were intentionally excluded from the analysis, throwing was still the most common mechanism of injury, and rotator cuff injuries were the most common injury. Labral tears were the most likely injury to be season ending and require surgery. Clinical Relevance This study is meant to help determine characteristics of shoulder injuries that occur in non‐pitchers by focusing on professional baseball batters and position players. This information could be helpful to sports medicine practitioners and shoulder specialists to better prognosticate injury recovery.
Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children’s Oncology Group phase I consortium study
Mueller, Sabine , Cooney, Tabitha , Yang, Xiaodong, Pal, Sharmistha , Gajjar, Amar , Liu, Xiaowei , Prem, Komal, Reid, Joel M. , Nelson, Marvin D. , Haas‐Kogan, Daphne A. , Fox, Elizabeth , Weigel, Brenda J. , Reid, Joel M , Haas-Kogan, Daphne , Yang, Xiaodong, Ermoian, Ralph P. , Minard, Charles G.

Mayo Clinic

Neuro-Oncology Advances | May 21, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac073 | PMID 35733515 Get It

AbstractBackgroundChildren with diffuse intrinsic pontine gliomas (DIPG) have a dismal prognosis. Adavosertib (AZD1775) is an orally available, blood-brain barrier penetrant, Wee1 kinase inhibitor. Preclinical efficacy against DIPG is heightened by radiation induced replication stress.MethodsUsing a rolling six design, 7 adavosertib dose levels (DLs) (50 mg/m2 alternating weeks, 50 mg/m2 alternating with weeks of every other day, 50 mg/m2, then 95, 130, 160, 200 mg/m2) were assessed. Adavosertib was only given on days of cranial radiation therapy (CRT).The duration of CRT (54 Gy over 30 fractions; 6 weeks) constituted the dose limiting toxicity (DLT) period. Endpoints included tolerability, pharmacokinetics, overall survival (OS) and peripheral blood γH2AX levels as a marker of DNA damage.ResultsA total of 46 eligible patients with newly diagnosed DIPG [median (range) age 6 (3–21) years; 52% female] were enrolled. The recommend phase 2 dose (RP2D) of adavosertib was 200 mg/m2/d during days of CRT. Dose limiting toxicity included ALT elevation (n = 1, DL4) and neutropenia (n = 1, DL7). The mean Tmax, T1/2 and Clp on Day 1 were 2 h, 4.4 h, and 45.2 L/hr/m2, respectively. Modest accumulation of adavosertib was observed comparing day 5 versus day 1 AUC0-8h (accumulation ratio = 1.6). OS was 11.1 months (95% CI: 9.4, 12.5) and did not differ from historical control.ConclusionAdavosertib in combination with CRT is well tolerated in children with newly diagnosed DIPG, however, compared to historical controls, did not improve OS. These results can inform future trial design in children with high-risk cancer.
Comparative cost-effectiveness of three post-radiofrequency ablation surveillance intervals for Barrett’s esophagus
Menon, Shyam , Mannath, Jayan, Iyer, Prasad G. , Ragunath, Krish , Norman, Richard

Mayo Clinic

Endoscopy International Open | May 21, 2022 | Volume: 10 | Issue: 08 | Pages: E1053-E1064

10.1055/a-1858-0945 | PMID 35979029 Get It

Abstract Background and study aims Radiofrequency ablation (RFA) for dysplastic Barrett’s esophagus (BE) has resulted in a paradigm shift in the management of BE. Despite widespread adoption of RFA, the optimal surveillance interval of the ablated zone is unclear. Methods A patient-level discrete time cycle Markov model was developed to model clinical surveillance strategies post-RFA for BE. Three surveillance strategies were examined: the American College of Gastroenterology (ACG) strategy based on ACG guidelines for post-RFA surveillance, the Cotton strategy based on data from the USA and UK RFA registries, and the UK strategy in line with surveillance strategies in UK centers. Monte-Carlo deterministic and probabilistic analyses were performed over 10,000 iterations (i. e., representing 10,000 patient journeys) and sensitivity analyses were carried out on the variables used in the model. Results On base-case analysis, the ACG strategy was the most cost-effective strategy, at a mean cost of £ 11,733 ($ 16,396) (standard deviation (SD) 1520.15) and a mean effectiveness of 12.86 (SD 0.07) QALYs. Probabilistic sensitivity analysis demonstrated that the ACG model was the most cost-effective strategy with a net monetary benefit (NMB) of £ 5,136 ($ 7177) (SD 241) compared to the UK strategy and a NMB of £ 7017 ($ 9,806) (SD 379) compared to the Cotton strategy. At a willingness to pay (WTP) threshold of £ 20,000 ($ 27,949), the ACG model was superior to the other strategies as the most cost-effective strategy. Conclusions A post-RFA surveillance strategy based on the ACG guidelines seems to be the most cost-effective surveillance option.
Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19
Puranik, Arjun, O’Horo, John C. , Pawlowski, Colin , Virk, Abinash , Kremers, Walter K. , Breeher, Laura E. , Gordon, Joel , Geyer, Holly L. , Speicher, Leigh L. , Challener, Doug W, Breeher, Laura, Gordon, Joel E, Speicher, Leigh Lewis, O'Horo, John C , Kremers, Walter K , Lenehan, Patrick J. , Swift, Melanie D. , Venkatakrishnan, A J , Challener, Douglas W. , Breeher, Laura , Soundararajan, Venky , Badley, Andrew D.

Mayo Clinic

PNAS Nexus | May 21, 2022 | Volume: 1 | Issue: 2 | Pages: No page available

10.1093/pnasnexus/pgac058 | PMID 36713311 Get It

Abstract COVID-19 vaccines are effective, but breakthrough infections have been increasingly reported. We conducted a test-negative case-control study to assess the durability of protection against symptomatic infection after vaccination with mRNA-1273. We fit conditional logistic regression (CLR) models stratified on residential county and calendar date of SARS-CoV-2 PCR testing to assess the association between the time elapsed since vaccination and the odds of symptomatic infection, adjusted for several covariates. There were 2,364 symptomatic individuals who had a positive SARS-CoV-2 PCR test after full vaccination with mRNA-1273 (“cases”) and 12,949 symptomatic individuals who contributed 15,087 negative tests after full vaccination (“controls”). The odds of symptomatic infection were significantly higher 250 days after full vaccination compared to the date of full vaccination (Odds Ratio [OR]: 2.47, 95% confidence interval [CI]: 1.19–5.13). The odds of non-COVID-19 associated hospitalization and non-COVID-19 pneumonia (negative control outcomes) remained relatively stable over the same time interval (Day 250 ORNon-COVID Hospitalization: 0.68, 95% CI: 0.47–1.0; Day 250 ORNon-COVID Pneumonia: 1.11, 95% CI: 0.24–5.2). The odds of symptomatic infection remained significantly lower almost 300 days after the first mRNA-1273 dose as compared to 4 days after the first dose, when immune protection approximates the unvaccinated state (OR: 0.26, 95% CI: 0.17–0.39). Low rates of COVID-19 associated hospitalization or death in this cohort precluded analyses of these severe outcomes. In summary, mRNA-1273 robustly protected against symptomatic SARS-CoV-2 infection at least 8 months after full vaccination, but the degree of protection waned over this time period.
Infected Intrathecal Pump Exchange with Preservation of Original Catheter in a Cancer Patient
Joseph, Amira , Bendel, Markus A. , Moeschler, Susan M. , Bendel, Markus, Moeschler, Susan

Mayo Clinic

Pain Medicine | May 20, 2022 | Volume: 23 | Issue: 11 | Pages: 1915-1920

10.1093/pm/pnac078 | PMID 35595252 Get It

In Response
McMullen, Kaley, Harbell, Monica W. , Kraus, Molly B.

Mayo Clinic

Anesthesia & Analgesia | May 20, 2022 | Volume: 134 | Issue: 6 | Pages: e39-e40

10.1213/ane.0000000000005997 | PMID 35595704 Get It

Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis
Strouse, Christopher , Ehlers, Shawna L. , Yost, Kathleen J. , Maurer, Matthew J. , Ansell, Stephen M. , Inwards, David J. , Johnston, Patrick B. , Micallef, Ivana N. , Link, Brian K. , Thompson, Carrie A. , Strouse, Christopher S , Yost, Kathleen , Maurer, Matthew , Ansell, Stephen M , Micallef, Ivana N , Link, Brian K , Farooq, Umar , Cerhan, James R , Thompson, Carrie A , Larson, Melissa C. , Cerhan, James R.

Mayo Clinic

JCO Oncology Practice | May 20, 2022 | Volume: 18 | Issue: 7 | Pages: e1069-e1080

10.1200/op.21.00694 | PMID 35594505 Get It

PURPOSE: This study assessed the long-term quality of life (QOL) of patients with aggressive lymphoma subtypes treated with autologous hematopoietic cell transplant (autoHCT) compared with those without history of transplant. METHODS: Patient-reported QOL measures were prospectively gathered from patients enrolled in the Iowa/Mayo Specialized Program of Research Excellence Molecular Epidemiology Resource cohort with aggressive lymphoma subtypes. QOL was measured using the Functional Assessment of Cancer Therapy-General (FACT-G), Functional Assessment of Chronic Illness Therapy–Fatigue Scale, State-Trait Anxiety Inventory (STAI), and Profile of Mood States instruments and with a numeric rating scale for overall QOL and spiritual QOL. The autoHCT group and no HCT groups were compared at 3 years (FU3) and 6 years (FU6) after lymphoma diagnosis. RESULTS: In total, 980 patients with lymphoma (106 autoHCT and 874 no HCT) diagnosed between 2002 and 2013 were included for analysis. The mean FACT-G total score was similar in the autoHCT and no HCT groups at FU3 (89.9 v 90.1, P = .64) and also at FU6 (91.5 v 89.6, P = .44). No differences between the autoHCT and no HCT groups were identified in the FACT subscales. The STAI identified lower anxiety in the autoHCT group by mean STAI1 (state) at FU3 (30.1 v 33.4, P < .01) and by mean STAI2 (trait) at FU6 (30.1 v 33.5, P = .02). No other clinically meaningful differences were identified between the two groups using the other QOL instruments. CONCLUSION: Patients remaining in remission at 3 and 6 years after diagnosis had a high level of QOL with no significant differences associated with history of treatment with autoHCT.
Reply: Does Reduction Mammaplasty for Treatment of Macromastia Play a Role in the Functionality and Performance of Female Athletes?
Kaplan, Jamie L. , Forte, Antonio J. , Forte, Antonio Jorge

Mayo Clinic

Plastic & Reconstructive Surgery | May 20, 2022 | Volume: 150 | Issue: 1 | Pages: 230e-231e

10.1097/prs.0000000000009211 | PMID 35594420 Get It